11:50 AM
 | 
Oct 27, 2017
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Bone's Allob meets in Phase I/IIa for delayed-union bone fractures

In September, Bone Therapeutics S.A. (Euronext:BOTHE) reported interim data from a Phase I/IIa trial in 16 patients with delayed-union fractures of long bones showing that Allob met the primary endpoint of improving radiological Tomographic Union Score (TUS) by ≥2 points or of improving clinical Global Disease Evaluation (GDE) by...

Read the full 225 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >